12 May 2022

COVID-19 vaccines safety update

Comirnaty (BioNTech Manufacturing GmbH)
Jcovden (previously COVID-19 Vaccine Janssen) (Janssen-Cilag International NV)
Nuvaxovid (Novavax CZ, a.s.)
Spikevax (Moderna Biotech Spain, S.L.)
Vaxzevria (AstraZeneca AB)

The safety of authorised COVID-19 vaccines is continuously monitored and updated information is regularly provided to the public.

Safety updates outline the outcomes from assessments of emerging worldwide safety data carried out mainly by EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) (section 1). They also outline how safety is monitored and contain high-level information on suspected adverse reaction reports, which PRAC takes into account in its assessments (section 2).

This safety update follows the update of 13 April 2022 and reflects the main assessment outcomes of the PRAC meeting held 02 to 05 May 2022.

EMA confirms that the benefits of all currently authorised COVID-19 vaccines continue to outweigh their side effects, given the risk of COVID-19 illness and related complications, including hospitalisation and death.
Key messages from the latest safety assessments

No updates to the product information for any of the authorised COVID-19 vaccines are currently warranted.

1. Latest safety assessments

**Comirnaty** (BioNTech Manufacturing GmbH)

There are currently no safety updates for Comirnaty.

---

**Jcovden** (Janssen-Cilag International NV)

There are currently no safety updates for Jcovden.

---

1 The European Centre for Disease Prevention and Control (ECDC) collects these exposure data from EU Member States as well as from the additional countries of the European Economic Area (EEA) Norway, Iceland and Liechtenstein.
languages); full information on the vaccine, including all identified side effects and advice on how to use it, is available in the product information (in all EU/EEA languages).

**Nuvaxovid** (Novavax CZ, a.s.)

There are currently no safety updates for Nuvaxovid.

About 178,000 doses of Nuvaxovid in adults were administered in the EU/EEA from authorisation to 24 April 2022.2

The initial marketing authorisation for Nuvaxovid in the EU was issued on 20 December 2021. Information on how Nuvaxovid works is provided in the medicine overview (in all EU/EEA languages); full information on the vaccine, including all identified side effects and advice on how to use it, is available in the product information (in all EU/EEA languages).

**Spikevax** (Moderna Biotech Spain, S.L.)

There are currently no safety updates for Spikevax.

About 153 million doses of Spikevax in adults and about 1.9 million doses of Spikevax in children and adolescents (below 18 years of age) were administered in the EU/EEA from authorisation to 24 April 2022.2

The initial marketing authorisation for Spikevax (previously COVID-19 Vaccine Moderna) in the EU was issued on 06 January 2021. Information on how Spikevax works is provided in the medicine overview (in all EU/EEA languages). Full information on the vaccine, including all identified side effects and advice on how to use it, is available in the product information (in all EU/EEA languages).

---

2 The European Centre for Disease Prevention and Control (ECDC) collects these exposure data from EU Member States as well as from the additional countries of the European Economic Area (EEA) Norway, Iceland and Liechtenstein.
Vaxzevria (AstraZeneca AB)

There are currently no safety updates for Vaxzevria.

About 69 million doses of Vaxzevria in adults were administered in the EU/EEA from authorisation to 24 April 2022.¹

The initial marketing authorisation for Vaxzevria (previously COVID-19 Vaccine AstraZeneca) in the EU was issued on 29 January 2021. Information on how Vaxzevria works is provided in the medicine overview (in all EU/EEA languages); full information on the vaccine, including all identified side effects and advice on how to use it, is available in the product information (in all EU/EEA languages).

2. How safety is monitored

Before COVID-19 vaccines were granted EU marketing authorisation, the efficacy and safety of the vaccines were assessed in pre-clinical studies and large clinical trials.

All relevant new information emerging worldwide on the vaccines since marketing authorisation is collected and promptly assessed. This is in line with the pharmacovigilance plan for COVID-19 vaccines of the EU regulatory network (comprising the regulatory bodies of the EU Member States, EMA and the European Commission).

EMA’s detailed assessments take into account all available data from all sources to draw robust conclusions on the safety of the vaccines. These data include clinical trial results, reports of suspected side effects, epidemiological studies monitoring the safety of the vaccine, toxicological investigations and any other relevant information.

Summary safety reports

The pharmacovigilance plan for COVID-19 vaccines includes monthly summary safety reports (MSSRs) which are compiled by the marketing authorisation holders to support timely and continuous benefit-risk evaluations for COVID-19 vaccines used during the pandemic. MSSRs are intended to be compiled in the first months of marketing. Afterwards, summary safety reports may cover time periods longer than a month or

¹ The European Centre for Disease Prevention and Control (ECDC) collects these exposure data from EU Member States as well as from the additional countries of the European Economic Area (EEA) Norway, Iceland and Liechtenstein.
Case reports of suspected side effects

Collecting reports of medical events and problems that occur following the use of a medicine, and therefore might be side effects, is one of the pillars of the EU safety monitoring system.

Healthcare professionals and vaccinated individuals are encouraged to report to their national competent authorities all suspected side effects individuals may have experienced after receiving a vaccine even if it is unclear whether the vaccine was the cause. For more information on how to report, including the importance of detailing the vaccine product name and the batch, see Reporting suspected side effects.

These spontaneous reports are collected in EudraVigilance, the EU database used for monitoring and analysing suspected side effects. Publicly available information can be accessed via EudraVigilance – European database of suspected drug reaction reports (in all EU/EEA languages).

As of 28 April 2022, EudraVigilance contained the following:

- **Comirnaty**: a total of 743,735 cases of suspected side effects spontaneously reported from EU/EEA countries; 7,765 of these reported a fatal outcome\(^4\,\,5\) (by 24 April 2022, about 627 million doses of Comirnaty had been given to people in the EU/EEA\(^6\))

- **Jcoviden**: a total of 48,410 cases of suspected side effects spontaneously reported from EU/EEA countries; 311 of these reported a fatal outcome\(^4\,\,5\) (by 24 April 2022, about 19.4 million doses of COVID-19 Vaccine Janssen had been administered to people in the EU/EEA\(^6\))

- **Nuvaxovid**: a total of 294 cases of suspected side effects spontaneously reported from EU/EEA countries; none of these reported a fatal outcome\(^4\,\,5\) (by 24 April 2022, about 178,000 doses of Nuvaxovid had been administered to people in the EU/EEA\(^6\))

- **Spikevax**: a total of 206,920 cases of suspected side effects spontaneously reported from EU/EEA countries; 1,025 of these reported

\(^4\) These figures have been calculated excluding cases reported from Northern Ireland (EU reporting requirements for suspected adverse reactions to EudraVigilance apply to Northern Ireland in accordance with the Protocol on Ireland/Northern Ireland).

\(^5\) Source: EudraVigilance. These figures cannot be extracted directly from the public database of suspected adverse reactions, which groups information per type of side effect. As more than one suspected side effect may have been included in a single case report, the total number of side effects will never match the number of individual cases. Similarly, this public database does not provide the total number of cases reported with a fatal outcome.

\(^6\) The European Centre for Disease Prevention and Control (ECDC) collects these exposure data from EU Member States as well as from the additional countries of the European Economic Area (EEA) Norway, Iceland and Liechtenstein.
COVID-19 vaccines safety update

a fatal outcome\(^7,8\) (by 24 April 2022, about 155 million doses of Spikevax had been given to people in the EU/EEA\(^9\))

- Vaxzevria: a total of 276,697 cases of suspected side effects spontaneously reported from EU/EEA countries; 1,529 of these reported a fatal outcome\(^7,8\) (by 24 April 2022, about 69 million doses of Vaxzevria had been given to people in the EU/EEA\(^9\)).

These reports describe suspected side effects in individuals, i.e. medical events observed following the use of a vaccine. The fact that someone has had a medical issue or died after vaccination does not necessarily mean that this was caused by the vaccine. This may have been caused, for example, by health problems not related to the vaccination.

The EU regulatory network continuously monitors EudraVigilance to detect any new safety issues. EudraVigilance relies on individual healthcare professionals and patients to report their own experience. The monitoring detects unusual or unexpected patterns in the reports received for further investigation and risk assessment.

Planned and ongoing studies

The companies that market COVID-19 vaccines continue to provide results from ongoing clinical trials. They also conduct additional studies to monitor the safety and effectiveness of the vaccines as they are used in vaccination campaigns and other clinical practice. For the list of planned and ongoing safety studies with COVID-19 vaccines, see the respective risk management plan: Comirnaty, Jcovden, Nuvaxovid, Spikevax and Vaxzevria.

A paediatric investigation plan (PIP) is in place for each authorised COVID-19 vaccine: Comirnaty, Jcovden, Nuvaxovid, Spikevax and Vaxzevria. The PIP describes how the company will collect data on the vaccine’s efficacy and safety for its potential use in children. Two vaccines, Comirnaty and Spikevax, are authorised for use in children.

---

\(^7\) These figures have been calculated excluding cases reported from Northern Ireland (EU reporting requirements for suspected adverse reactions to EudraVigilance apply to Northern Ireland in accordance with the Protocol on Ireland/Northern Ireland).

\(^8\) Source: EudraVigilance. These figures cannot be extracted directly from the public database of suspected adverse reactions, which groups information per type of side effect. As more than one suspected side effect may have been included in a single case report, the total number of side effects will never match the number of individual cases. Similarly, this public database does not provide the total number of cases reported with a fatal outcome.

\(^9\) The European Centre for Disease Prevention and Control (ECDC) collects these exposure data from EU Member States as well as from the additional countries of the European Economic Area (EEA) Norway, Iceland and Liechtenstein.
In addition, EMA is coordinating observational studies in EU Member States looking at real-world data from clinical practice to monitor the safety and effectiveness of COVID-19 vaccines, including in pregnant women.